Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Kiora Pharmaceuticals, Inc. <KPRX.OQ> expected to post a loss of 62 cents a share - Earnings Preview
Kiora Pharmaceuticals, Inc. KPRX.OQ KPRX.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Kiora Pharmaceuticals, Inc. is for a loss of 62 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kiora Pharmaceuticals, Inc. is $12.00, about 363.3% above its last closing price of $2.59
This summary was machine generated August 4 at 12:57 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing